Novo Nordisk weight-loss drug new indication approval plus dividend hike: GLP-1 tailwinds and high dividends resonate
Another Major Catalyst for the GLP-1 SectorIn early August 2026, a major piece of news hit the global pharmaceutical industry: Novo Nordisk's star GLP-1 drug Wegovy officially received FDA...
Read Full Article

